Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Mon...
Biomea Fusion, Inc. (BMEA)
Company Research
Source: Yahoo! Finance
Strong correlation between C-peptide increase and HbA1c reduction (r = -0.73, p Best response observed in prespecified, beta-cell deficient patients on one or more antihyperglycemic agents at baseline, achieving a statistically significant placebo-adjusted mean reduction in HbA1c of 1.47% at Week 26 (p=0.022), after only 12 weeks of 100 mg once daily icovamenib Preclinical in vivo experiments indicated that icovamenib enhanced the responsiveness of human islets to GLP-1-based medicines, consistent with the increase in expression levels (transcript and protein) of both the GLP-1 receptor and intracellular insulin Severe Insulin Deficient Diabetes represents an underserved patient population within type 2 diabetes and is estimated to be over 100 million pe
Read more
Impact Snapshot
Event Time:
BMEA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMEA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMEA alerts
High impacting Biomea Fusion, Inc. news events
Weekly update
A roundup of the hottest topics
BMEA
News
- Biomea Fusion, Inc. (NASDAQ: BMEA) was given a new $10.00 price target on by analysts at Oppenheimer Holdings Inc..MarketBeat
- Biomea Fusion Announces Leadership TransitionGlobeNewswire
- Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.MarketBeat
- Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last DoseGlobeNewswire
- Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.MarketBeat
BMEA
Earnings
- 7/31/24 - In-Line
BMEA
Sec Filings
- 3/28/25 - Form 4
- 3/27/25 - Form 8-K
- 2/28/25 - Form 8-K
- BMEA's page on the SEC website